Summary
This study developed a serum-based diagnostic classifier using 20 microRNAs (miRNAs) to detect lung adenocarcinoma with high sensitivity and specificity. Validation in an independent cohort demonstrated 89.1% sensitivity and 94.9% specificity, with particularly strong performance in early-stage (Stage I) detection at 90.8%. The classifier showed organ-specific utility, detecting other lung cancer histotypes at moderate rates whilst demonstrating low cross-reactivity with non-lung cancers, suggesting potential clinical application for lung cancer screening and diagnosis.
UK applicability
The findings may be relevant to UK lung cancer diagnostic procedures, particularly for early detection protocols. However, clinical translation would require validation in UK populations and integration with existing National Health Service screening and diagnostic pathways.
Key measures
Sensitivity (89.1%), specificity (94.9%), area under the curve (0.958), detection rates for squamous cell carcinoma (70.4%) and large cell carcinoma (70.0%), cross-cancer organ specificity
Outcomes reported
The study developed and validated a 20 miRNA-based serum diagnostic classifier for lung adenocarcinoma detection. The classifier achieved 89.1% sensitivity and 94.9% specificity in an independent validation cohort, with notably high accuracy (90.8%) for Stage I cases.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.